Efficacy of breast cancer screening in the community according to risk level

Journal of the National Cancer Institute

Volumn 97, Issue 14, 2005, Pages 1035-1043

  Elmore, Joann G ^a,b,c   Reisch, Lisa M ^a   Barton, Mary B ^f   Barlow, William E ^b,c,i   Rolnick, Sharon ^e   Harris, Emily L ^d   Herrinton, Lisa J ^h   Geiger, Ann M ^g   Beverly, R Kevin ^b   Hart, Gene ^b   Yu, Onchee ^b   Greene, Sarah M ^b   Weiss, Noel S ^c   Fletcher, Suzanne W ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^f HARVARD PILGRIM HEALTH CARE   (United States)

^g Research and Evaluation   (United States)

^h DIVISION OF RESEARCH   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EXAMINATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL RECORD; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNITED STATES; BREAST TUMOR; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RADIOGRAPHY; RISK; STATISTICAL MODEL;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; ODDS RATIO; RESEARCH DESIGN; RISK ASSESSMENT; UNITED STATES;

EID: 23244451672     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji183     Document Type: Article

References (43)

1. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med 2003;348:1672-80.
2. National Guidelines Clearinghouse. http://www.guidelines.gov. [Last accessed: October 2004.]
3. Moss S. Atrial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen 1999;6:144-8.
4. Joy JE, Penhoet EE, Petitti DB. Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis (Prepublication). Washington, D.C.: The National Academies Press; 2004.
5. Morrison AS. Case definition in case-control studies of the efficacy of screening. Am J Epidemiol 1982;115:6-8.
6. Weiss NS. Control definition in case-control studies of the efficacy of screening and diagnostic testing. Am J Epidemiol 1983;118:457-60.
7. Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 1998;51: 81-91.
8. International Classification of Diseases, Ninth Revision (ICD-9). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. 1979.
9. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
10. Reisch LM, Fosse JS, Beverly K, Yu O, Barlow WE, Harris EL, et al. Training, quality assurance, and assessment of medical record abstraction in a multisite study. Am J Epidemiol 2003;157:546-51.
11. Charlson M, Pompei P, Ales K, MacKenzie C. Anew method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
12. Woodman CB, Threlfall AG, Boggis CR, Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region. BMJ 1995;310: 224-6.
13. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983;118:865-86.
14. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations. J Clin Oncol 2001;19:3490-9.
15. Duffy SW, Day NE, Tabar L, Chen HH, Smith TC. Markov models of breast tumor progression: Some age-specific results. J Natl Cancer Inst Monogr 1997:93-7.
16. Weiss NS. Application of the case-control method in the evaluation of screening. Epidemiol Rev 1994;16:102-8.
17. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd Edition ed: John Wiley & Sons; 2000.
18. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
19. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-2.
20. Screening mammography re-evaluated. Lancet 2000;355:747-52.
21. Screening for breast cancer with mammography. Lancet 2001;358:2164-8.
22. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.
23. Basinski, A. Review: High-quality studies do not show reductions in breast cancer mortality for women screened with mammography. Review of Gostzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34. ACP Journal Club. 2000 Sept-Oct;133:6.
24. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338:1089-96.
25. Baines CJ. Mammography screening: Are women really giving informed consent? J Natl Cancer Inst 2003;95:1508-11.
26. Oestreicher N, White E, Lehman CD, Mandelson MT, Porter PL, Taplin SH. Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat 2002;76:73-81.
27. Bobo JK, Lee NC, Thames SF. Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000;92:971-6.
28. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005;293:1245-56.
29. Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)-Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ 1999;48:1-22.
30. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351: 1451-67.
31. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352: 930-42.
32. Moss M. Blurred vision: Doctors are weak link. The New York Times; 2002.
33. Elmore J, Wells C, Howard D. The association between radiologists' experience and performance in mammographic interpretation. J Women's Health 1998;7:443-9.
34. Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, et al. Comparison of screening mammography in the United States and the United Kingdom. JAMA 2003;290:2129-37.
35. Elmore JG, Nakano CY, Koepsell TD, Desnick LM, D'Orsi CJ, Ransohoff DF. International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 2003;95: 1384-93.
36. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, et al. Improving the accuracy of mammography: Volume and outcome relationships. J Natl Cancer Inst 2002;94:369-75.
37. Elmore JG, Carney PA. Does practice make perfect when interpreting mammography? J Natl Cancer Inst 2002;94:321-3.
38. Beam CA, Conant EF, Sickles EA. Association of volume and volume-independent factors with accuracy in screening mammogram interpretation. J Natl Cancer Inst 2003;95:282-90.
39. Elmore JG, Miglioretti DL, Carney PA. Does practice make perfect when interpreting mammography? Part II. J Natl Cancer Inst 2003;95:250-2.
40. Potosky AL, Merrill RM, Riley GF, Taplin SH, Barlow W, Fireman BH, et al. Breast cancer screening survival and treatment in HMO and fee-for-service settings. J Natl Cancer Inst 1997;89:1683-91.
41. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
42. Miller AB. Commentary: A defence of the Health Insurance Plan (HIP) study and the Canadian National Breast Screening Study (CNBSS). Int J Epidemiol 2004;33:64-5; discussion 9-73.
43. Clarke M, Collins R, Darby S, Davies C, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.